Literature DB >> 21789127

Which patients with renal cancer may benefit from sunitinib therapy?

Tom Ferguson1, Martin Gore.   

Abstract

Entities:  

Year:  2010        PMID： 21789127      PMCID： PMC3126012          DOI： 10.1177/1758834009359411

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  21 in total

1.  A new system for grading recommendations in evidence based guidelines.

Authors:  R Harbour; J Miller
Journal:  BMJ       Date:  2001-08-11

2.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Brain metastases in patients with renal cell cancer receiving new targeted treatment.

Authors:  Helgi H Helgason; Henk A Mallo; Helga Droogendijk; John G Haanen; Astrid A M van der Veldt; Alfonsus J van den Eertwegh; Epie Boven
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 5.  Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.

Authors:  S E DePrimo; C Bello
Journal:  Ann Oncol       Date:  2007-09       Impact factor: 32.976

6.  Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Authors:  Arkadiusz Z Dudek; Jakub Zolnierek; Anu Dham; Bruce R Lindgren; Cezary Szczylik
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

7.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

8.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Authors:  Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell
Journal:  J Urol       Date:  2008-12-18       Impact factor: 7.450

9.  VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

Authors:  Dan G Duda; Tracy T Batchelor; Christopher G Willett; Rakesh K Jain
Journal:  Trends Mol Med       Date:  2007-04-25       Impact factor: 11.951

10.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544
View more
  2 in total

Review 1.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

Review 2.  Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.

Authors:  Sungkyoung Kim; Wenping Ding; Lian Zhang; Wei Tian; Siyu Chen
Journal:  Onco Targets Ther       Date:  2014-05-12       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.